Literature DB >> 34998797

Cortical excitability changes as a marker of cognitive impairment in Parkinson's disease.

Nitish Kamble1, Amitabh Bhattacharya1, Shantala Hegde2, N Vidya2, Mohit Gothwal2, Ravi Yadav1, Pramod Kumar Pal3.   

Abstract

Cognitive impairment of different severity with eventual progression to dementia in Parkinson's disease (PD) appears during the course of the disease. In this study, transcranial magnetic stimulation (TMS) was used to assess cortical excitability changes in PD patients with varying cognitive impairment. We aimed to identify the TMS parameters that could serve as a non-invasive marker of cognitive impairment in patients with PD. Consecutive PD patients were recruited in the study. Detailed neuropsychological assessment was carried out to identify PD without cognitive impairment (PD-nC), PD with mild cognitive impairment (PD-MCI) and PD with dementia (PDD). Twenty patients of PDD (2 females and 18 males), 20 PD-MCI (4 females and 16 males), 18 PD-nC (5 females, 13 males) and 18 healthy controls (4 females, and 14 males) were included in the study. All the participants underwent TMS with recording of resting motor threshold, central motor conduction time, silent period, short interval intracortical inhibition (SICI) and intracortical facilitation (ICF). All the groups were age matched. The SICI was present in all; however, significantly greater inhibition was noted in PDD (Mean±SD; 0.11 ± 0.08) followed by PD-MCI (0.31 ± 0.17), PD-nC (0.49 ± 0.26) and controls (0.61 ± 0.23; p < 0.001). The ICF was significantly reduced in PDD (Mean±SD; 0.15 ± 0.18), PD-MCI (0.55 ± 0.31), PD-nC (0.96 ± 0.59), when compared to healthy controls (1.81 ± 0.83; p < 0.001). Patients with PD-nC, PD-MCI and PDD had graded reduction in ICF and increasing intracortical inhibition as the disease progressed from PD-nC through PD-MCI to PDD. This suggests progressive overactivity of GABAergic transmission, glutaminergic deficiency with consequent reduction of cholinergic transmission leading to dementia.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cortical excitability; Intracortical facilitation; Parkinson’s disease; Short interval intracortical inhibition; Transcranial magnetic stimulation

Mesh:

Year:  2022        PMID: 34998797      PMCID: PMC7613142          DOI: 10.1016/j.bbr.2022.113733

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.352


  57 in total

Review 1.  Transcranial magnetic stimulation in neurology.

Authors:  Masahito Kobayashi; Alvaro Pascual-Leone
Journal:  Lancet Neurol       Date:  2003-03       Impact factor: 44.182

2.  The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA.

Authors:  Giuseppe Lanza; Raffale Ferri
Journal:  Adv Pharmacol       Date:  2019-01-18

3.  Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans.

Authors:  V Di Lazzaro; A Oliviero; E Saturno; M Dileone; F Pilato; R Nardone; F Ranieri; G Musumeci; T Fiorilla; P Tonali
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

4.  Cortical inhibition in Parkinson's disease. A study with paired magnetic stimulation.

Authors:  A Berardelli; S Rona; M Inghilleri; M Manfredi
Journal:  Brain       Date:  1996-02       Impact factor: 13.501

5.  The effect of voluntary contraction on cortico-cortical inhibition in human motor cortex.

Authors:  M C Ridding; J L Taylor; J C Rothwell
Journal:  J Physiol       Date:  1995-09-01       Impact factor: 5.182

Review 6.  New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: the potential role of glutamate, gamma-aminobutyric acid, and glycine.

Authors:  Pierre-Hervé Luppi; Olivier Clément; Sara Valencia Garcia; Frédéric Brischoux; Patrice Fort
Journal:  Sleep Med       Date:  2013-06-19       Impact factor: 3.492

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study.

Authors:  A P Strafella; F Valzania; S A Nassetti; A Tropeani; A Bisulli; M Santangelo; C A Tassinari
Journal:  Clin Neurophysiol       Date:  2000-07       Impact factor: 3.708

9.  The glutamate antagonist riluzole suppresses intracortical facilitation.

Authors:  J Liepert; P Schwenkreis; M Tegenthoff; J P Malin
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

10.  Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale.

Authors:  Jaime Kulisevsky; Ramón Fernández de Bobadilla; Javier Pagonabarraga; Saül Martínez-Horta; Antonia Campolongo; Carmen García-Sánchez; Berta Pascual-Sedano; Roser Ribosa-Nogué; Carolina Villa-Bonomo
Journal:  Parkinsonism Relat Disord       Date:  2013-06-15       Impact factor: 4.891

View more
  1 in total

1.  Reduced Intracortical Facilitation to TMS in Both Isolated REM Sleep Behavior Disorder (RBD) and Early Parkinson's Disease with RBD.

Authors:  Giuseppe Lanza; Filomena Irene Ilaria Cosentino; Bartolo Lanuzza; Mariangela Tripodi; Debora Aricò; Michela Figorilli; Monica Puligheddu; Francesco Fisicaro; Rita Bella; Raffaele Ferri; Manuela Pennisi
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.